Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

Presentation TCT 2023

TCT 423: Long-term Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition with Evolocumab and Aortic Stenosis Events – An Analysis from FOURIER and FOURIER-OLE

Presenter: Prakriti Gaba

October 26, 2023

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Todd Neale

September 19, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

Presentation ACC 2023

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Presenter: Annapoorna S. Kini

March 06, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2023

Caitlin E. Cox

February 01, 2023

News Daily News

PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial

Todd Neale

January 18, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

Advertisement

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

TCT 423: Long-term Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition with Evolocumab and Aortic Stenosis Events – An Analysis from FOURIER and FOURIER-OLE

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

LDL Control Remains Poor in CAD Patients: NHANES

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

TCTMD’s Top 10 Most Popular Stories for January 2023

PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content